Preeclampsia Epidemiology Summary

• Preeclampsia is a complex pregnancy disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. It is believed to stem from placental dysfunction, leading to systemic endothelial activation and inflammatory responses that affect maternal circulation. Preeclampsia is more prevalent in first-time mothers, women with a family history of the condition, and those with preexisting health issues such as hypertension or diabetes.
• In 2025, the 7MM accounted for more than ~450,000 preeclampsia incident cases, with the US contributing nearly 65% of the total cases.
• In 2025, sub-type specific cases of preeclampsia in Japan were distributed as follows: late-onset preeclampsia accounted for the majority, with ~90%, while early-onset preeclampsia accounted for the remaining ~10%.
• Despite significant progress in understanding preeclampsia, predicting its occurrence, particularly for term and postpartum forms, remains a major challenge.
• In 2025, the US reported approximately 75% mild preeclampsia cases and 25% severe cases among severity-specific cases.
• Incorporating patient perspectives is vital for developing more effective care strategies for women affected by preeclampsia. Understanding the personal experiences, concerns, and needs of these women provides valuable insights that can help healthcare providers tailor interventions to be more compassionate and responsive.
• According to World Health Organization (2025), preeclampsia is a hypertensive disorder that affects 3-8% of women who give birth worldwide.
• Guidelines from the American College of Obstetricians and Gynecologists (ACOG), International Society for the Study of Hypertension in Pregnancy (ISSHP), and World Health Organization (WHO) standardize preeclampsia diagnosis and management; however, definitions still differ, as ISSHP considers uteroplacental dysfunction a diagnostic feature, whereas ACOG does not, affecting case identification and limiting cross-country prevalence comparisons.

DelveInsight’s “Preeclampsia Epidemiology Forecast – 2036” report delivers an in depth understanding of preeclampsia, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Preeclampsia Disease Understanding

Preeclampsia Overview

Hypertensive disorders of pregnancy constitute a leading cause of maternal and perinatal mortality worldwide. Preeclampsia, with or without severe features, is a disorder of pregnancy associated with new-onset hypertension, usually with accompanying proteinuria, which occurs most often after 20 weeks of gestation and frequently near term. This disease represents a spectrum of hypertensive disease in pregnancy, beginning with gestational hypertension and progressing to develop severe features, ultimately leading to its more severe manifestations, such as eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. Early diagnosis and prompt management are essential to preventing both maternal and neonatal complications through symptomatic management and delivery planning.

Preeclampsia Diagnosis

Diagnosis of preeclampsia is based on new-onset hypertension (systolic blood pressure =140 mmHg or diastolic =90 mmHg) accompanied by either proteinuria (=0.3 g in a 24-h urine specimen or a protein-to-creatinine ratio >0.3) or evidence of maternal organ dysfunction, such as renal or liver impairment, pulmonary edema, or visual disturbances, while severe preeclampsia is defined by higher thresholds (systolic =160 mmHg or diastolic =110 mmHg on two occasions at least 4 h apart, proteinuria =5 g/24 h) or by features such as thrombocytopenia, elevated liver enzymes, and persistent unexplained abdominal pain.

Further details are provided in the report...

Preeclampsia Epidemiology

Key Findings from Preeclampsia Epidemiological Analysis and Forecast

• According to DelveInsight's analysis, the US had nearly ~230,000 diagnosed incident cases of preeclampsia in 2025, and this number is projected to rise in the coming years.
• In the US, the 25-29 years age group accounted for the largest number of preeclampsia cases, with nearly ~68,000 cases in 2025, followed by the =39 years age group with ~67,000 cases and the 30-34 years age group with ~64,000 cases, while the 20-24 years, 35-39 years, and =20 years age groups accounted for ~48,000, 34,000, and ~15,000 cases, respectively.
• In 2025, sub-type specific cases of preeclampsia in EU4 and the UK were distributed as follows: late-onset preeclampsia accounted for the majority, with ~90%, while early-onset preeclampsia accounted for the remaining ~10%.
• In 2025, the US reported approximately 75% mild preeclampsia cases and 25% severe cases among severity-specific cases.
• In the study by Ohseto H et al. (2026), preeclampsia prevalence is approximately 2.7% in Japan among pregnant women.
• A scoping review published in 2026 in Frontiers in Cardiovascular Medicine estimated preeclampsia prevalence in the WHO European Region at 2.5%, based on nationally representative studies with data collected from 2004 to 2023.
• In 2025, Germany accounted for the highest share of preeclampsia cases among EU4 and the UK at nearly 26%, closely followed by France at 25%. The UK ranked third with nearly 20% of cases, followed by Italy with 15%, while Spain had the lowest share at 12%. Across all five countries, mild preeclampsia accounted for nearly 75% of cases and severe preeclampsia for about 25%.

Industry Experts and Physician Views for Preeclampsia

To keep up with preeclampsia dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the preeclampsia epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the University of California, Harvard Medical School, Nagoya City University, Japan, St. Joseph's Health Care, UK and Clinical Research Center (ECRC), Germany etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in Preeclampsia.

Scope of the Preeclampsia Epidemiology Report

• The report covers a segment of an executive summary, a descriptive overview of preeclampsia, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Preeclampsia Epidemiology Report Insights

• Preeclampsia Patient Population Forecast

Preeclampsia Epidemiology Report Key Strengths

• Epidemiology based (Epi based) Bottom up Forecasting
• 11-year forecast
• Patient Burden Trends (by Geography)
• The 7MM Coverage

Explore DelveInsight’s Preeclampsia Market Forecast to 2036 for comprehensive epidemiological insights, disease burden analysis, emerging therapies, and future market opportunities.

FAQs

• Preeclampsia Epidemiology Epidemiology Insights
• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of preeclampsia cases?
• What are the disease risks and burdens of preeclampsia?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of preeclampsia at the 7MM level?

Reasons to Buy Preeclampsia Epidemiology Report

• Insights on preeclampsia burden and disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the preeclampsia epidemiology analysis and patient population trends.